HOME >> MEDICINE >> NEWS
New class of targeted cancer drugs shows promise in slowing progression of recurrent prostate cancer

paradigm for cancer treatment, and is a promising area of research. This study must be viewed cautiously, however, as we are comparing statistics from historical control groups.

Pertuzumab is a single-agent antibody designed to bind to the HER2 receptor and inhibit the ability of HER2 to pair with other HER family members (HER1, HER2, HER3 and HER4). If the pairing process (called dimerization) is not interrupted, the binding of these growth factors activates an intracellular signaling pathway that leads to tumor proliferation.

While other drugs such as docetaxel have shown to benefit men with advanced prostate cancer, no other second-line therapy (a treatment given when an initial treatment (first-line therapy) does not work or stops working) to date has shown to prolong survival.

Previous research published by cancer researchers at Cedars-Sinai and other institutions has shown that pertuzumab affects the growth of several other types of cancers, including breast, ovarian and lung cancer, and that the drug may also prolong survival for patients with advanced ovarian cancer.

In the current study, the pertuzumab was well-tolerated but no objective tumor shrinkages were observed. No decline in PSA (prostate-specific antigen; a tumor marker) levels was detected in patients during the study. According to the researchers, this study raises a question long debated in prostate cancer literature: what should clinical outcome standards or end point be the for studies involving patients with advanced, intractable prostate cancer who have limited treatment options.

The next step for researchers is to test the pertuzumab on a larger group of patients in a randomized fashion, and to analyze data that is not retrospective.

Prostate cancer is the most common type of cancer found in American men, other than skin cancer and is the second leading cause of cancer death in men. The American Cancer Society estim
'"/>

Contact: Simi Singer
simi.singer@cshs.org
310-423-4768
Cedars-Sinai Medical Center
16-Feb-2007


Page: 1 2 3

Related medicine news :

1. W.M. Keck Foundation announces 2007 class of Distinguished Young Scholars in medical research
2. Early-morning Friday classes may prevent students from getting sloppy on thirsty Thursdays
3. Panel offers guidelines on skin reactions to new class of cancer drugs
4. UK researchers find new class of nontoxic cancer treatments
5. New class of HIV drug attacks previously untargeted enzyme
6. Sleep disturbances affect classroom performance
7. Simple classification can help define and predict limb-threatening diabetic infections
8. World-class Biomedical Research Center to be in West London
9. A new way of classifying addictive drugs
10. Phys ed class more effective when theres more talking
11. W.M. Keck Foundation announces 2006 class of Distinguished Young Scholars in Medical Research

Post Your Comments:
(Date:2/26/2015)... NJ (PRWEB) February 26, 2015 A ... The practice is offering the following 50 year ... $90 for their choice of Sonic Care Diamond Clean ... $199, $179 respectively). The cost is $2895 for ... that require more than ten treatment procedures are priced ...
(Date:2/26/2015)... Scotch Plains, NJ (PRWEB) February 26, 2015 ... a “NJ Top Dentist” for Dr. David Caggiano! ... education, experience and interests. Combining his background in ... seven years of experience as a general dentist allows ... the toughest orthodontic situations. He was named Orthodontic ...
(Date:2/26/2015)... The hip resurfacing procedure at Texas ... resident John Short to resume his active lifestyle, it has ... climb Mt. Kilimanjaro, the highest free-standing mountain in the world, ... in his late 20s, Short suffered from early onset degeneration. ... sockets were bone on bone. , Then about five ...
(Date:2/26/2015)... CA (PRWEB) February 26, 2015 Beckman ... “Diversity of extracellular vesicles and their cargo in cell-to-cell ... vesicles and their relevance for cell-to-cell communication. The webinar ... March 4, 2015 at 8:00am PT. , Every cell ... extracellular vesicles (EVs) , often called “exosomes” or “microvesicles.” ...
(Date:2/26/2015)... 2015 2015 Deep Market Research ... and in-depth study on the current state of ... focus on the Chinese situation. , Major companies ... & Co.KG, Hu-Friedy, Medisporex, Towne Brothers, Teleflex Medical, ... Weirong Medical Equipment, Shuanglu, Changshu Henry Medical Instrument, ...
Breaking Medicine News(10 mins):Health News:A Beautiful Smile Dentistry is Celebrating 50 Years in Practice! 2Health News:A Beautiful Smile Dentistry is Celebrating 50 Years in Practice! 3Health News:Dr. David Caggiano of Caggiano Orthodontics is Celebrating Five Years as an "NJ Top Dentist" ! 2Health News:Dr. David Caggiano of Caggiano Orthodontics is Celebrating Five Years as an "NJ Top Dentist" ! 3Health News:Hip Resurfacing at Texas Orthopedics Enables Patient to Climb Mt. Kilimanjaro 2Health News:Hip Resurfacing at Texas Orthopedics Enables Patient to Climb Mt. Kilimanjaro 3Health News:Beckman Coulter Webinar Series Presents Diversity of Extracellular Vesicles and Their Cargo in Cell-to-cell Communication 2Health News:Beckman Coulter Webinar Series Presents Diversity of Extracellular Vesicles and Their Cargo in Cell-to-cell Communication 3Health News:Global Hemostat Industry Data, Size and Growth Report 2015-2020 Now Available at DeepResearchReports.com 2Health News:Global Hemostat Industry Data, Size and Growth Report 2015-2020 Now Available at DeepResearchReports.com 3
(Date:2/26/2015)... Editor Note: For more ... Investor-Edge has initiated coverage on the following ... Teva Pharmaceutical Industries Ltd (NYSE: TEVA ), ... Inc. (NYSE: AGN ), and Depomed Inc. ... Johnson and Johnson can be accessed at http://get.Investor-Edge.com/pdf/?c=Johnson%20and%20Johnson&d=26-Feb-2015&s=JNJ ...
(Date:2/26/2015)... , Feb. 26, 2015  MEI Pharma, Inc. (Nasdaq: ... clinical development of novel therapies for cancer, announced today that ... Officer, will present at the Cowen and Company 35 th ... at 10:40 a.m. Eastern time from the Boston Marriott Copley ... at www.meipharma.com . A replay will be available approximately ...
(Date:2/26/2015)... CITY , Feb. 26, 2015  Great Basin ... launched a "best efforts" follow-on offering of up to ... of one share of Series E preferred stock and ... preferred stock will be convertible into four shares of ... exercisable into one share of common stock at an ...
Breaking Medicine Technology:Updates on Pharma Stocks -- Johnson and Johnson, Teva Pharma Industries, Endo Intl., Allergan, and Depomed 2Updates on Pharma Stocks -- Johnson and Johnson, Teva Pharma Industries, Endo Intl., Allergan, and Depomed 3Updates on Pharma Stocks -- Johnson and Johnson, Teva Pharma Industries, Endo Intl., Allergan, and Depomed 4Updates on Pharma Stocks -- Johnson and Johnson, Teva Pharma Industries, Endo Intl., Allergan, and Depomed 5MEI Pharma to Present at Cowen and Company Health Care Conference 2MEI Pharma to Present at Cowen and Company Health Care Conference 3Great Basin Scientific, Inc. Announces Commencement of Public Offering 2Great Basin Scientific, Inc. Announces Commencement of Public Offering 3
Cached News: